Cagrilintide: Evidence, Mechanism, Dosing & Legal Status

Cagrilintide (development code AM833; the amylin half of CagriSema) is a Novo Nordisk long-acting, acylated amylin analogue engineered for once-weekly subcutaneous dosing.7 Unlike most peptides discussed for body composition, it is supported by real human RCTs rather than animal extrapolation — which is exactly why this monograph treats it differently. The headline is not whether it works, but how it works, how strong the human data are, and the fact that it is not yet a legal product.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Cagrilintide is an investigational drug not approved by any regulator for sale; its only legitimate use is within a registered clinical trial. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is cagrilintide and how does it work?

Cagrilintide is a 37-residue amylin analogue built on a pramlintide-like backbone (chosen over human amylin to reduce amyloid fibrillation), with substitutions to suppress aggregation and a C20 fatty-diacid acylation attached via a linker to an N-terminal lysine that confers reversible albumin binding — the same long-acting strategy used in semaglutide.7 Native amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells that governs satiety, gastric emptying and post-prandial glucagon; the approved amylin analogue pramlintide requires thrice-daily dosing because its half-life is only about 20 to 45 minutes. Cagrilintide's reversible albumin binding stretches that to roughly 159 to 195 hours (about 7 to 8 days), enabling once-weekly use.1

Mechanistically, cagrilintide is a non-selective agonist at amylin receptors — heteromers formed when the calcitonin receptor combines with receptor activity-modifying proteins (RAMP1/2/3), generating subtypes AMY1R, AMY2R and AMY3R — and at the calcitonin receptor itself.7 It acts centrally on hindbrain and hypothalamic circuits, with the area postrema as the primary site, then signaling through the nucleus of the solitary tract and lateral parabrachial nucleus, with additional input to hypothalamic AgRP/POMC neurons.8 In RAMP1/RAMP3 knockout mice, cagrilintide's neuronal activation and its body-weight-lowering effect were abolished, establishing that amylin receptors 1 and 3 are necessary for the weight loss — a Grade C mechanistic finding from animal work.8 Notably, weight loss persisted even after acute food-intake suppression faded, implicating an energy-expenditure component, and the loss was driven by fat-mass reduction with relative lean preservation.8 Because it engages a satiety pathway that does not overlap with GLP-1, cagrilintide is additive with semaglutide — the rationale for the CagriSema combination.9

What is the human evidence by indication?

Cagrilintide's evidence base is anchored by genuine randomized controlled trials, which is what distinguishes it sharply from most peptides marketed for body composition. The table below summarizes the picture; every weight-management row is graded A on the strength of phase 2 and phase 3 human RCTs.

The phase 2 monotherapy dose-finding trial (Lau et al., Lancet 2021) randomized 906 people across 57 sites and 10 countries over 26 weeks, showing a clear dose response from 6.0% at 0.3 mg up to 10.8% at 4.5 mg versus 3.0% for placebo; cagrilintide 4.5 mg even edged out once-daily liraglutide 3.0 mg.2 The phase 1b combination study had already produced the first human signal of additive benefit, with up to 17.1% weight loss when cagrilintide was added to semaglutide.1

The pivotal data come from REDEFINE 1 (Garvey et al., NEJM 2025; registered as NCT05567796), which enrolled 3,417 adults with obesity or overweight plus at least one comorbidity and no type 2 diabetes over 68 weeks. On the trial-product estimand, CagriSema produced 22.7% weight loss versus 11.8% for cagrilintide alone, 16.1% for semaglutide alone and 2.3% for placebo; more than 40% of CagriSema patients lost at least 25% of body weight.3 Body-composition substudy data showed fat mass falling 35.7% and lean soft-tissue 14.4%.4 The companion REDEFINE 2 trial (Davies et al., NEJM 2025), in 1,206 adults with obesity plus type 2 diabetes, produced 13.7% weight loss with more than 80% of CagriSema patients reaching HbA1c at or below 6.5%.56

What doses appear in the literature?

Reported strictly as information, not a protocol — cagrilintide is unapproved and should not be self-administered. It is given subcutaneously once weekly, supported by the roughly 7-to-8-day half-life; as a peptide it is not orally bioavailable, so the SC route is used throughout the development program.1 The phase 2 trial evaluated 0.3, 0.6, 1.2, 2.4 and 4.5 mg weekly with stepwise dose escalation; although 4.5 mg gave the greatest monotherapy effect, 2.4 mg is the dose carried into CagriSema and the phase 3 component arms.2 The CagriSema regimen is a fixed dose of cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly, gradually titrated; REDEFINE 1 used flexible, tolerability-driven dose adjustment.9 Stepwise escalation exists specifically to mitigate the dose-related gastrointestinal adverse events characteristic of amylin and GLP-1 agents.1 There is no legitimate compounded or research-chemical preparation: the trial product is a manufactured sterile injectable, and the FDA prohibits cagrilintide compounding.11

How safe is cagrilintide?

The most common adverse events are gastrointestinal, dose-related, and mostly mild to moderate and transient. In the phase 1b combination study, about one-third of adverse events were GI and injection-site reactions were the second most common, all mild; in phase 2 monotherapy, GI adverse events occurred in 41% to 63% of cagrilintide groups versus 32% with placebo.12 In phase 3 REDEFINE 1, overall GI events were 79.6% with CagriSema versus 39.9% with placebo (nausea 55% vs 12.6%; vomiting 26.1% vs 4.1%), described as mostly transient, with discontinuation due to adverse events of 6.0% versus 3.7%.3 Across REDEFINE 1 and 2, adverse-event-driven discontinuation stayed below 10% and the overall profile was consistent with the GLP-1 drug class.9

From a functional and integrative lens, a body-composition caveat matters: in REDEFINE 1, roughly 40% of the weight lost was lean soft-tissue (lean −14.4% vs fat −35.7%), consistent with the incretin class — a reminder that adequate protein intake and resistance training support body-composition quality during rapid weight loss, even though net composition still favored fat loss.3 As a combination partner, CagriSema also inherits GLP-1 class cautions including gallbladder events and the class concern around medullary thyroid carcinoma; amylin agonism itself has no established tumor signal, but long-term oncologic and cardiovascular safety await longer trials.13 Pregnancy and lactation were exclusion criteria with no human safety data and should be avoided.2

What is the FDA and anti-doping status in 2026?

As of mid-2026 cagrilintide is investigational with no approval for any indication. Novo Nordisk submitted a New Drug Application for CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg, once-weekly SC) for chronic weight management on 18 December 2025, with FDA review expected during 2026; a separate diabetes regulatory pathway is planned pending further data.910 The critical compounding point: cagrilintide is not a component of any FDA-approved drug and has not been found safe and effective, so the FDA's position is that it cannot be used in compounding under federal law, and it has never appeared on an FDA bulk-drug-substance list.11 Vendors selling cagrilintide "for laboratory use only" are operating outside the legal framework; it is not a lawful dietary-supplement ingredient.12

For athletes the safe assumption is prohibition. Cagrilintide is not individually named on the WADA Prohibited List, but anti-doping authorities broadly treat unapproved investigational peptides as prohibited, and research-chemical labeling confers no protection.12 Any tested athlete or military service member should assume cagrilintide is banned unless specifically verified; it is not a DEA-scheduled controlled substance, but that does not make it permitted in sport.12

Bottom line. Cagrilintide is the unusual case of a peptide with real, large, peer-reviewed human RCTs behind it — graded A — that delivers clinically meaningful weight loss, especially as the combination CagriSema. What is hyped is the stand-alone "fat-loss peptide" framing; its main value is as a combination partner, hard cardiovascular outcomes are not yet in, and CagriSema narrowly missed Novo Nordisk's own internal target. Legally, the most important fact is that cagrilintide is not approved anywhere as of mid-2026, is explicitly ineligible for compounding, and any research-chemical supply sits outside both the law and the safety net the clinical trials provide. Regulatory facts here are current as of June 2026; the FDA decision on the CagriSema NDA was pending at the time of writing and should be re-verified after that date.